A Guide for Selection of Genetic Instruments in Mendelian Randomization Studies of Type 2 Diabetes and HbA1c: Toward an Integrated Approach

被引:11
|
作者
Garfield, Victoria [1 ]
Salzmann, Antoine [1 ]
Burgess, Stephen [2 ,3 ]
Chaturvedi, Nish [1 ]
机构
[1] UCL, Inst Cardiovasc Sci, IMRC Unit Lifelong Hlth & Ageing, London, England
[2] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England
[3] Univ Cambridge, MRC Biostat Unit, Cambridge, England
基金
英国惠康基金; 英国医学研究理事会;
关键词
GLYCEMIC TRAITS; GENOME-WIDE; RISK; ADIPOSITY; DEMENTIA; OUTCOMES;
D O I
10.2337/db22-0110
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study we examine the instrument selection strategies currently used throughout the type 2 diabetes and HbA(1c) Mendelian randomization (MR) literature. We then argue for a more integrated and thorough approach, providing a framework to do this in the context of HbA(1c) and diabetes. We conducted a literature search for MR studies that have instrumented diabetes and/or HbA(1c). We also used data from the UK Biobank (UKB) (N = 349,326) to calculate instrument strength metrics that are key in MR studies (the F statistic for average strength and R-2 for total strength) with two different methods ("individual-level data regression" and Cragg-Donald formula). We used a 157-single nucleotide polymorphism (SNP) instrument for diabetes and a 51-SNP instrument (with partition into glycemic and erythrocytic as well) for HbA(1c). Our literature search yielded 48 studies for diabetes and 22 for HbA(1c). Our UKB empirical examples showed that irrespective of the method used to calculate metrics of strength and whether the instrument was the main one or included partition by function, the HbA(1c) genetic instrument is strong in terms of both average and total strength. For diabetes, a 157-SNP instrument was shown to have good average strength and total strength, but these were both substantially lesser than those of the HbA(1c) instrument. We provide a careful set of five recommendations to researchers who wish to genetically instrument type 2 diabetes and/or HbA(1c). In MR studies of glycemia, investigators should take a more integrated approach when selecting genetic instruments, and we give specific guidance on how to do this.
引用
收藏
页码:175 / 183
页数:10
相关论文
共 50 条
  • [31] Type 2 Diabetes: Nordic Walking has no effect on HbA1c
    Halle, Martin
    DIABETOLOGIE UND STOFFWECHSEL, 2011, 6 (01) : 24 - 24
  • [32] Could HbA1c have a role in the diagnosis of type 2 diabetes?
    Manley, S. E.
    Stratton, I. M.
    Nightingale, P. G.
    Round, R. A.
    Smith, J. M.
    Gough, S. C. L.
    DIABETOLOGIA, 2007, 50 : S370 - S370
  • [33] HbA1c negatively correlates with LCAT activity in type 2 diabetes
    Nakhjavani, Manouchehr
    Esteghamati, Alireza
    Esfahanian, Fatemeh
    Ghanei, Azam
    Rashidi, Armin
    Hashemi, Saeideh
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 81 (01) : 38 - 41
  • [34] Managing Type 2 Diabetes: Balancing HbA1c and Body Weight
    Mavian, Annie A.
    Miller, Stephan
    Henry, Robert R.
    POSTGRADUATE MEDICINE, 2010, 122 (03) : 106 - 117
  • [35] Tools for Practice Screening and diagnosis of type 2 diabetes with HbA1c
    Mannarino, Marco
    Tonelli, Marcello
    Allan, G. Michael
    CANADIAN FAMILY PHYSICIAN, 2013, 59 (01) : 42 - 42
  • [36] Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes
    Monnier, L
    Colette, C
    Thuan, JF
    Lapinski, H
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (04) : 231 - 235
  • [37] Impact of therapeutic education on the value of HbA1c in type 2 diabetes
    Mustapha, O. K.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [38] Correlation Between HbA1c and Albuminuria in Type 2 Diabetes Mellitus
    Merlin, Jesika
    Pusparini
    MAJALAH KEDOKTERAN BANDUNG-MKB-BANDUNG MEDICAL JOURNAL, 2020, 52 (03): : 125 - 130
  • [39] Should HbA1c POCT be accepted for diagnosis of type 2 diabetes?
    Lenters-Westra, E.
    CLINICA CHIMICA ACTA, 2019, 493 : S743 - S744
  • [40] Effects of finerenone in patients with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability and duration of diabetes
    McGill, J. B.
    Agarwal, R.
    Anker, S. D.
    Bakris, G. L.
    Filippatos, G.
    Pitt, B.
    Ruilope, L. M.
    Birkenfeld, A. L.
    Caramori, M. L.
    Brinker, M.
    Joseph, A.
    Lage, A.
    Lawatscheck, R.
    Scott, C.
    Rossing, P.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S318 - S318